scholarly journals Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis

2018 ◽  
Vol 9 ◽  
Author(s):  
Neelam Srivastava ◽  
Angelo B. Cefalu ◽  
Maurizio Averna ◽  
Rai A. K. Srivastava
Keyword(s):  
Cholesterol Efflux ◽  
Plasma Cholesterol ◽  
Cholesterol Efflux Capacity ◽  
Hdl Functionality ◽  
Fecal Cholesterol

Improved plasma cholesterol efflux capacity from human macrophages in patients with hyperalphalipoproteinemia

2014 ◽  
Vol 234 (1) ◽  
pp. 193-199 ◽  
Author(s):  
Petra El Khoury ◽  
Wanee Plengpanich ◽  
Eric Frisdal ◽  
Wilfried Le Goff ◽  
Weerapan Khovidhunkit ◽  
...  
Keyword(s):  
Cholesterol Efflux ◽  
Plasma Cholesterol ◽  
Human Macrophages ◽  
Cholesterol Efflux Capacity

scholarly journals Elevated CETP Activity Improves Plasma Cholesterol Efflux Capacity From Human Macrophages in Women

2012 ◽  
Vol 32 (10) ◽  
pp. 2341-2349 ◽  
Author(s):  
Elise F. Villard ◽  
Petra El Khoury ◽  
Emilie Duchene ◽  
Dominique Bonnefont-Rousselot ◽  
Karine Clement ◽  
...  
Keyword(s):  
Cholesterol Efflux ◽  
Plasma Cholesterol ◽  
Human Macrophages ◽  
Cholesterol Efflux Capacity

scholarly journals Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART

2015 ◽  
Vol 56 (3) ◽  
pp. 692-702 ◽  
Author(s):  
Petra El Khoury ◽  
Mathilde Ghislain ◽  
Elise F. Villard ◽  
Wilfried Le Goff ◽  
Caroline Lascoux-Combe ◽  
...  
Keyword(s):  
Cholesterol Efflux ◽  
Plasma Cholesterol ◽  
Cholesterol Efflux Capacity

scholarly journals Improving of HDL capacity for macrophages cholesterol efflux after plasma incubation with phospholipid nanoparticles

2018 ◽  
Vol 64 (3) ◽  
pp. 253-256
Author(s):  
V.A. Kudinov ◽  
T.S. Zakharova ◽  
T.I. Torkhovskaya ◽  
V.A. Kashirtseva ◽  
G.E. Morosevich ◽  
...  
Keyword(s):  
Blood Plasma ◽  
Cholesterol Efflux ◽  
Particle Diameter ◽  
Hdl Cholesterol ◽  
Apo B ◽  
Cholesterol Efflux Capacity ◽  
Phospholipid Nanoparticles ◽  
Hdl Functionality ◽  
Apoprotein A1

In connection with recent data about antiatherogenic importance of not only plasma HDL concentration, but of their cell cholesterol efflux capacity as well, the possibility of its correction by phospholipid (PL) nanoparticles was studied. Blood plasma was incubated with earlier elaborated PL nanoparticles emulsion with the particle diameter up to 30 nm, and HDL cholesterol efflux capacity of apo B-depleted plasma was studied. Using macrophages THP-1 preloaded 3H-cholesterol were used. The addition of incubated plasma supernatants with the elevated PL/apo A-1 ratio to cell media resulted in almost increase in two fold 3H-cholesterol efflux as compared with native HDL. The maximal efflux was observed at the PL/apo A-1 ratio of 1.06 as compared with native apo B-depleted plasma (the PL/apo A-1 ratio of 0.85). Results suggest possible usage of ultrasmall PL nanoparticles for regeneration of impaired antiatherogenic HDL functionality. This approach seems to be predominant compared with the usage of PL emulsions with detergent or apoprotein A1.

scholarly journals High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 574
Author(s):  
Maria Pia Adorni ◽  
Nicoletta Ronda ◽  
Franco Bernini ◽  
Francesca Zimetti
Keyword(s):  
High Density Lipoprotein ◽  
Cholesterol Efflux ◽  
Current Knowledge ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
High Density ◽  
Current Evidence ◽  
Endocrine Disorders ◽  
Lifestyle Modifications ◽  
Cholesterol Efflux Capacity

Over the years, the relationship between high-density lipoprotein (HDL) and atherosclerosis, initially highlighted by the Framingham study, has been revealed to be extremely complex, due to the multiple HDL functions involved in atheroprotection. Among them, HDL cholesterol efflux capacity (CEC), the ability of HDL to promote cell cholesterol efflux from cells, has emerged as a better predictor of cardiovascular (CV) risk compared to merely plasma HDL-cholesterol (HDL-C) levels. HDL CEC is impaired in many genetic and pathological conditions associated to high CV risk such as dyslipidemia, chronic kidney disease, diabetes, inflammatory and autoimmune diseases, endocrine disorders, etc. The present review describes the current knowledge on HDL CEC modifications in these conditions, focusing on the most recent human studies and on genetic and pathophysiologic aspects. In addition, the most relevant strategies possibly modulating HDL CEC, including lifestyle modifications, as well as nutraceutical and pharmacological interventions, will be discussed. The objective of this review is to help understanding whether, from the current evidence, HDL CEC may be considered as a valid biomarker of CV risk and a potential pharmacological target for novel therapeutic approaches.

Sign in / Sign up

Export Citation Format

Share Document